Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Serina Therapeutics Inc.

    NYSE: SER · Real-Time Price · USD
    5.95
    0.00 (0.00%)
    At close: Jun 06, 2025, 3:44 PM
    6.49
    9.08%
    After-hours: Jun 06, 2025, 05:46 PM EDT

    Serina Therapeutics Statistics

    Share Statistics

    Serina Therapeutics has 9.97M shares outstanding. The number of shares has increased by 18.05% in one year.

    Shares Outstanding

    n/a
    		 9.97M

    Shares Change (YoY)

    n/a
    		 18.05%

    Shares Change (QoQ)

    n/a
    		 11.7%

    Owned by Institutions (%)

    n/a
    		 n/a

    Shares Floating

    n/a
    		 n/a

    Failed to Deliver (FTD) Shares

    n/a
    		 177

    FTD / Avg. Volume

    n/a
    		 1.56%

    Short Selling Information

    The latest short interest is 29.44K, so 0.3% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 29.44K

    Short % of Shares Out

    n/a
    		 0.3%

    Short % of Float

    n/a
    		 0.51%

    Short Ratio (days to cover)

    n/a
    		 10.45

    Valuation Ratios

    The PE ratio is -3.31 and the forward PE ratio is -3.89. Serina Therapeutics's PEG ratio is 0.01.

    PE Ratio

    n/a
    		 -3.31

    Forward PE

    n/a
    		 -3.89

    PS Ratio

    n/a
    		 658.37

    Forward PS

    n/a
    		 827.6

    PB Ratio

    n/a
    		 57.52

    P/FCF Ratio

    n/a
    		 -2.15

    PEG Ratio

    n/a
    		 0.01
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Serina Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 2.4, with a Debt / Equity ratio of 0.42.

    Current Ratio

    n/a
    		 2.4

    Quick Ratio

    n/a
    		 2.4

    Debt / Equity

    n/a
    		 0.42

    Debt / EBITDA

    n/a
    		 -0.03

    Debt / FCF

    n/a
    		 -0.02

    Interest Coverage

    n/a
    		 -32.41

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $4,666.67

    Profits Per Employee

    n/a
    		 $-928,416.67

    Employee Count

    n/a
    		 12

    Asset Turnover

    n/a
    		 0.01

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -40.41% in the last 52 weeks. The beta is 0.7, so Serina Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.7

    52-Week Price Change

    n/a
    		 -40.41%

    50-Day Moving Average

    n/a
    		 5.56

    200-Day Moving Average

    n/a
    		 5.7

    Relative Strength Index (RSI)

    n/a
    		 55.89

    Average Volume (20 Days)

    n/a
    		 11,347

    Income Statement

    In the last 12 months, Serina Therapeutics had revenue of 56K and earned -11.14M in profits. Earnings per share was -1.51.

    Revenue

    n/a
    		 56K

    Gross Profit

    n/a
    		 -138K

    Operating Income

    n/a
    		 -17.05M

    Net Income

    n/a
    		 -11.14M

    EBITDA

    n/a
    		 -10.49M

    EBIT

    n/a
    		 -10.68M

    Earnings Per Share (EPS)

    n/a
    		 -1.51
    Full Income Statement

    Balance Sheet

    The company has 3.67M in cash and 268K in debt, giving a net cash position of 3.4M.

    Cash & Cash Equivalents

    n/a
    		 3.67M

    Total Debt

    n/a
    		 268K

    Net Cash

    n/a
    		 3.4M

    Retained Earnings

    n/a
    		 -44.32M

    Total Assets

    n/a
    		 6.73M

    Working Capital

    n/a
    		 3.4M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -17.14M and capital expenditures -22K, giving a free cash flow of -17.16M.

    Operating Cash Flow

    n/a
    		 -17.14M

    Capital Expenditures

    n/a
    		 -22K

    Free Cash Flow

    n/a
    		 -17.16M

    FCF Per Share

    n/a
    		 -2.33
    Full Cash Flow Statement

    Margins

    Gross margin is -246.43%, with operating and profit margins of -30442.86% and -19894.64%.

    Gross Margin

    n/a
    		 -246.43%

    Operating Margin

    n/a
    		 -30442.86%

    Pretax Margin

    n/a
    		 -20012.5%

    Profit Margin

    n/a
    		 -19894.64%

    EBITDA Margin

    n/a
    		 -18726.79%

    EBIT Margin

    n/a
    		 -30442.86%

    FCF Margin

    n/a
    		 -30641.07%

    Dividends & Yields

    SER does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for SER is $11, which is 89.3% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $11

    Price Target Difference

    n/a
    		 89.3%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 1
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Mar 15, 2024. It was a backward split with a ratio of 7:250.

    Last Split Date

    n/a
    		 Mar 15, 2024

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 7:250

    Scores

    Altman Z-Score

    n/a
    		 -3.32

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist